IL226449A0 - Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof - Google Patents

Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Info

Publication number
IL226449A0
IL226449A0 IL226449A IL22644913A IL226449A0 IL 226449 A0 IL226449 A0 IL 226449A0 IL 226449 A IL226449 A IL 226449A IL 22644913 A IL22644913 A IL 22644913A IL 226449 A0 IL226449 A0 IL 226449A0
Authority
IL
Israel
Prior art keywords
valsartan
preparation
lercanidipine hydrochloride
complex formulation
formulation
Prior art date
Application number
IL226449A
Other languages
Hebrew (he)
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL226449(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of IL226449A0 publication Critical patent/IL226449A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL226449A 2010-12-09 2013-05-20 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof IL226449A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
IL226449A0 true IL226449A0 (en) 2013-07-31

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226449A IL226449A0 (en) 2010-12-09 2013-05-20 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Country Status (17)

Country Link
EP (1) EP2648730A4 (en)
KR (1) KR101414814B1 (en)
CN (1) CN103249415B (en)
AR (1) AR084195A1 (en)
AU (1) AU2011339150B2 (en)
BR (1) BR112013013415A2 (en)
CL (1) CL2013001626A1 (en)
CO (1) CO6721030A2 (en)
DO (1) DOP2013000115A (en)
EA (1) EA201390844A1 (en)
IL (1) IL226449A0 (en)
MX (1) MX2013005716A (en)
PE (1) PE20140699A1 (en)
SG (1) SG190326A1 (en)
UA (1) UA108277C2 (en)
UY (1) UY33772A (en)
WO (1) WO2012077968A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (en) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 Compound preparation of lercanidipine and atorvastatin
CA2903961A1 (en) * 2013-03-12 2014-09-18 Lg Life Sciences Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
US11382866B2 (en) * 2017-07-06 2022-07-12 Mankind Pharma Ltd. Fixed dose pharmaceutical composition of valsartan and sacubitril
KR102233986B1 (en) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 Solid pharmaceutical composition comprising lafutidine and irsogladin and process for producing thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
KR20060125824A (en) * 2003-12-01 2006-12-06 라이프사이클 파마 에이/에스 Pharmaceutical compositions comprising lercanidipine
JP5110697B2 (en) * 2005-06-27 2012-12-26 第一三共株式会社 Solid preparation
KR100888131B1 (en) * 2006-10-10 2009-03-11 한올제약주식회사 Combination preparation for Cardiovascular disease therapy by Chronotherapy theory.

Also Published As

Publication number Publication date
WO2012077968A3 (en) 2012-07-26
UY33772A (en) 2012-07-31
EP2648730A4 (en) 2014-08-06
SG190326A1 (en) 2013-06-28
EA201390844A1 (en) 2013-11-29
MX2013005716A (en) 2013-06-12
WO2012077968A2 (en) 2012-06-14
DOP2013000115A (en) 2014-07-31
BR112013013415A2 (en) 2019-09-24
PE20140699A1 (en) 2014-06-13
KR20120089787A (en) 2012-08-13
KR101414814B1 (en) 2014-07-21
EP2648730A2 (en) 2013-10-16
CL2013001626A1 (en) 2013-10-04
AU2011339150B2 (en) 2015-09-10
AR084195A1 (en) 2013-04-24
CN103249415A (en) 2013-08-14
AU2011339150A1 (en) 2013-06-06
CN103249415B (en) 2017-12-12
UA108277C2 (en) 2015-04-10
CO6721030A2 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
IL269804A (en) Protein-active agent conjugates and method for preparing the same
GB2477588B (en) Self-making bread method, bread machine and bread ingredient box thereof
GB201116610D0 (en) A copolymer and preparation method and application thereof
EP2657188A4 (en) Fluorographene and preparation method thereof
IL216171A (en) Lipid compound, method for its preparation, a pharmaceutical composition and a lipid composition comprising the same and uses thereof
EP2578584A4 (en) Arylamino purine derivatives, preparation method and pharmaceutical use thereof
EP2603546A4 (en) Polysiloxane-polylactide block copolymer and preparation method thereof
AP3222A (en) Germination-stimulant carbamate derivatives and process for preparation thereof
EP2573072A4 (en) Indenoquinolone compound, preparation method and use thereof
EP2607076A4 (en) Perspective film and preparing method thereof
ZA201400188B (en) Substituted cinnamamide derivative, preparation method and use thereof
EP2786982A4 (en) Amino-propylene-glycol derivatives, preparation method and pharmaceutical composition and use thereof
EP2924042A4 (en) Bis- -carboline compound and preparation method, pharmaceutical composition and use thereof
AP2013006842A0 (en) Lubricating composition and method for the preparation thereof
EP2781512A4 (en) Oxadiazole compound and preparation method thereof, pharmaceutical composition and use thereof
ZA201206740B (en) Aildenafil citrate crystal form o,preparation method and use thereof
IL226449A0 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
EP2636675A4 (en) Diphosphonate compounds and preparation method and use thereof
EP2837380A4 (en) Lercanidipine hydrochloride and losartan potassium compound preparation and preparation method thereof
EP2634184A4 (en) C-arylglucoside derivative, preparation method therefor, and use thereof
HK1186185A1 (en) Imidazole derivatives and preparation method and use thereof
EP2617293A4 (en) Bitterness-masking ingredient and bitterness-masking method
EP2565180A4 (en) Alpha-arylmethoxyacrylate derivative, preparation method thereof, and pharmaceutical composition containing same
PL2736496T3 (en) Pharmaceutical composition containing an antimuscarinic agent and method for the preparation thereof
ZA201108148B (en) Triazine-aryl-bis-indoles and process for preparation thereof